Cargando…
Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid
BACKGROUND: Pembrolizumab, a programmed cell death protein 1 checkpoint inhibitor, is a novel drug used to treat a variety of advanced malignancies. However, it can also result in many immune-related adverse events, with cutaneous toxicities being the most frequent. Regarding pembrolizumab-induced s...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022695/ https://www.ncbi.nlm.nih.gov/pubmed/36937423 http://dx.doi.org/10.3389/fonc.2023.1095694 |